Valuation: Mylan Inc

Market Cap 2TCr 1.79TCr 1.67TCr 1.52TCr 2.85TCr 1,94000Cr 2.88TCr 20TCr 7.84TCr 99TCr 7.52TCr 7.36TCr 3,17000Cr P/E 2026 *
75.1x
P/E 2027 * 42.9x
Enterprise Value 3.2TCr 2.86TCr 2.66TCr 2.42TCr 4.55TCr 3,09700Cr 4.6TCr 32TCr 13TCr 1,57400Cr 12TCr 12TCr 5,06200Cr EV / Sales 2026 *
2.16x
EV / Sales 2027 * 2.04x
Free-Float
91.44%
Yield 2026 *
2.92%
Yield 2027 * 2.99%
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.61%+1.72%+38.30%+106.93% 1,04300Cr
-0.76%-0.84%+35.21%+62.70% 62TCr
+0.39%+4.81%+17.81%+83.77% 48TCr
-0.29%-0.99%+64.79%+37.06% 35TCr
+1.22%+3.41%+21.76%+42.52% 34TCr
+0.91%+2.15%+11.46%+34.85% 27TCr
+1.33%+1.58%-6.82%+11.07% 24TCr
-1.37%+0.04%+38.29%+52.33% 22TCr
+0.17%-0.27%+24.40%+96.82% 18TCr
Average +0.02%+0.28%+27.25%+58.67% 41.63TCr
Weighted average by Cap. -0.31%+0.60%+30.61%+69.18%

Financials

2026 *2027 *
Net sales 1.48TCr 1.32TCr 1.23TCr 1.12TCr 2.11TCr 1,43200Cr 2.13TCr 15TCr 5.79TCr 73TCr 5.55TCr 5.43TCr 2,34100Cr 1.5TCr 1.34TCr 1.25TCr 1.14TCr 2.14TCr 1,45600Cr 2.16TCr 15TCr 5.88TCr 74TCr 5.65TCr 5.52TCr 2,38000Cr
Net income 14Cr 13Cr 12Cr 11Cr 20Cr 1.37TCr 20Cr 141.55Cr 55Cr 696.49Cr 53Cr 52Cr 2.24TCr 30Cr 27Cr 25Cr 23Cr 42Cr 2.89TCr 43Cr 298.46Cr 116.74Cr 1.47TCr 112.04Cr 109.61Cr 4.72TCr
Net Debt 1.2TCr 1.07TCr 995.59Cr 904.38Cr 1.7TCr 1,15700Cr 1.72TCr 12TCr 4.68TCr 59TCr 4.49TCr 4.39TCr 1,89200Cr 1.07TCr 954.11Cr 890.08Cr 808.54Cr 1.52TCr 1,03500Cr 1.54TCr 11TCr 4.18TCr 53TCr 4.01TCr 3.92TCr 1,69100Cr
Logo Mylan Inc
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Mylan Inc